My opinion is that the fatty liver issues posed with AEGR's drug will prevent a positive vote and ISIS will come out on top even with reduced efficacy. Thoughts?
The FDA really should approve both, with REMS to play it safe. That way patients have a choice.
Watch for ISIS to take a hit on AEGR approval, then bounce right back on the ISIS approval.